ورود
مقالات فارسیISIکنفرانسهاژورنالها

Anti-LINGO -۱ improved remyelination and neurobehavioral deficit in cuprizone-induced demyelination

محل انتشار: مجله علوم پایه پزشکی ایران، دوره: 24، شماره: 7
سال انتشار: 1400
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 237

فایل این مقاله در 8 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:
https://civilica.com/doc/1252788

شناسه ملی سند علمی:

JR_IJBMS-24-7_005

تاریخ نمایه سازی: 19 مرداد 1400

چکیده مقاله:

Objective(s): Central nervous system demyelination is the main feature of multiple sclerosis (MS).  The most important unmet need in MS is use of treatments that delay the progression of the disease. Leucine-rich repeat and Immunoglobulin-like domain containing NOGO receptor-interacting protein ۱(LINGO-۱) have been known as inhibitors of oligodendrocyte differentiation and myelination.Materials and Methods: We investigated LINGO-۱ antibody effects on remyelination and neurobehavioral deficit using cuprizone-induced demyelination. Animals were randomly divided into three groups (n = ۱۰): (۱) Control group; received the regular diet, (۲) CPZ group; normal saline was injected intraperitoneally, and (۳) Treatment group; LINGO-۱ antibody (۱۰ mg/kg) was injected IP once every six days for ۳ weeks. We assessed the level of myelin basic protein (MBP), neurofilament heavy chain (NF۲۰۰), and Brain-derived neuroprotective factor (BDNF) in the corpus callosum (CC) by immunostaining against MBP, NF۲۰۰, and BDNF. Results: We found  decreased levels of MBP, NF۲۰۰, and BDNF in demyelinated CC, and anti-LINGO-۱ treatment improved demyelinated structures. Furthermore, motor impairment was measured by Open-field (OFT) and Balance beam tests. In the treatment group, motor impairment was significantly improved. Conclusion: These results provide evidence that LINGO-۱ antibody can improve remyelination and neurobehavioral deficit.

کلیدواژه ها:

Brain-derived neurotrophic factor ، Cuprizone ، Multiple Sclerosis ، Myelin basic protein ، Nogo Receptor ۱ ، Remyelination

نویسندگان

Khadijeh Moradbeygi

Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, Department of Nursing, Abadan Faculty of Medical Sciences, Abadan, Iran

Mohsen Parviz

Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Hossein Rezaeizadeh

Department of Traditional Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran

Arman Zargaran

Department of Traditional Pharmacy, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran

Mohammad Ali Sahraian

Department of Neurology, Neuroscience Institute, MS Research Center, Tehran University of Medical Sciences, Tehran, Iran

Shima Mehrabadi

Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Marjan Nikbakhtzadeh

Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Elham Zahedi

Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Zhan J, Mann T, Joost S, Behrangi N, Frank M, ...
  • Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A,Vukusic ...
  • Münzel EJ, Williams A. Promoting remyelination in multiple sclerosis-recent advances. ...
  • Nadeem M, Sklover L, A Sloane J. Targeting remyelination treatment ...
  • Ava G, Bartolomei I, Costantino A, Berra M, Venturoli S, ...
  • Sena A, Couderc R, Vasconcelos JC, Ferret-Sena V, Pedrosa R. ...
  • Ineichen BV, Plattner P S, Good N, Roland M, Linnebank M, Schwab ME . Nogo-A ...
  • Noor NA, Fahmy HM, Mohammed FF, Elsayed AA, Radwan NM. ...
  • Mohamed A, Al-Kafaji G, Almahroos A, Almosawi Z, Alalwan H, ...
  • Khademi M, Dring AM, Gilthorpe JD, Wuolikainen A, Al Nimer ...
  • Martinez B, V Peplow Ph. Protective effects of pharmacological therapies in ...
  • Kremer D, Akkermann R, Küry P, Dutta R. Current advancements ...
  • Cunniffe N, Coles A. Promoting remyelination in multiple sclerosis. J ...
  • Zeis T, Probst A, Steck AJ, Stadelmann C, Brück W, ...
  • Irvine KA, Blakemore WF. Remyelination protects axons from demyelination associated ...
  • L. Andrews J, Fernandez-Enright F. A decade from discovery to ...
  • Mandai K, Guo T, St Hillaire C, Meabon JS, Kanning ...
  • Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, ...
  • Wang J, Sui RX, Miao Q, et al. Effect of ...
  • Rémy F, Mirrashed F, Campbell B, Richter W. Verbal episodic ...
  • Mi S, Hu B, Hahm K, Luo Y, Kam Hui ...
  • Sun JJ, Ren QG, Xu L and Zhang Zh-J. LINGO-۱ antibody ameliorates ...
  • Shao Z, Lee X, Huang G, Sheng G, Henderson CE, ...
  • Gresle MM, Liu Y, Kilpatrick TJ, Kemper D, Wu QZ, ...
  • Zendedel A, Beyer C, Kipp M. Cuprizone-induced demyelination as a ...
  • Xu H, Yang HJ, Zhang Y, Clough R, Browning R, ...
  • Zhu K, Sun J, Kang Zh, Zou Z, Wu G ...
  • Sun J, Zhou H, Bai F, Ren Q, Zhang Z. ...
  • Benardais K, Kotsiari A, Skuljec J, Koutsoudaki PN, Gudi V, ...
  • Mi S, Miller RH, Tang W, Lee X, Hu B, ...
  • Lee X, Yang Z, Shao Z, Rosenberg SS, Levesque M, ...
  • Sestakova N, Puzserova A, Kluknavsky M, Bernatova I. Determination of ...
  • Luong TN, Carlisle HJ, Southwell A and Patterson PH. Assessment ...
  • Buddeberg BS, Kerschensteiner M, Merkler D, Stadelmann C, Schwab ME. ...
  • Tagge I, O’Connor A, Chaudhary P, Pollaro J, Berlow Y, ...
  • Honarvar F, Hojati V, Bakhtiari N, Vaezi G, Javan M. ...
  • Glenn JD, Smith MD, Kirby LA, Baxi EG, Whartenby KA. ...
  • Mozafari S, Sherafat MA, Javan M, Mirnajafi-Zadeh J, Tiraihi T. ...
  • Zhou Y, Simpson S Jr, Charlesworth JC, van der Mei ...
  • Vega-Riquer JM, Mendez-Victoriano G, Morales-Luckie RA, Gonzalez-Perez O. Five decades ...
  • Al-Chalabi A, Miller CC. Neurofilaments and neurological disease. Bioessays ۲۰۰۳; ...
  • Varhaug KN, Torkildsen Ø, Myhr KM, Vedeler CA. Neurofilament light ...
  • Petzold A, Gveric D, Groves M, et al. Phosphorylation and ...
  • Gudi V, Gai L, Herder V, Tejedor LS, Kipp M, ...
  • Voskuhl RR, Itoh N, Tassoni A, Matsukawa MA, Ren E, ...
  • Fulmer CG, VonDran MW, Stillman AA, Huang Y, Hempstead BL, ...
  • Pifarré P, Gutierrez-Mecinas M, Prado J, Usero L, Roura-Mir C, ...
  • VonDran MW, Singh H, Honeywell JZ, Dreyfus CF. Levels of ...
  • Mohammadi-Rad M, Ghasemi N, Aliomrani M. Evaluation of apamin effects ...
  • Fahmy H M, Noor NA, F. Mohammed F, A. Elsayed ...
    • نمایش کامل مراجع